Purpose To provide an update on recent advances in the management of patients with
multiple myeloma who are not eligible for autologous stem-cell transplantation. Methods A …

1Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation
Trust, Bristol, 2Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds …

Multiple myeloma (MM) accounts for 1% of all cancers and $10% of all haematological
malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at …

Abstract The European Myeloma Network provides recommendations for the management
of the most common complications of multiple myeloma. Whole body low-dose computed …

Multiple myeloma accounts for 1.6% of all cancer cases and approximately 10% of
hematologic malignancies in the United States. In 2015, an estimated 28,850 new cases of …

The guideline was drafted by a writing group identified by the Haemostasis and Thrombosis
Task Force of the British Committee for Standards in Haematology (BCSH). All the authors …

A temporary discontinuation (drug holiday) of high-dose antiresorptive (AR) agents has
been proposed to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ) …

During the last few years, several new drugs have been introduced for treatment of patients
with multiple myeloma, which have significantly improved treatment outcome. All of these …

No comprehensive evaluation has been made to assess the risk of viral and bacterial
infections among patients with monoclonal gammopathy of undetermined significance …

Immunoglobulin (Ig) replacement therapy dramatically changed the clinical course of
primary hypogammaglobulinemias, significantly reducing the incidence of infectious events …